CDA and familial pancreatic carcinoma: Recently, some additional interesting results have been reported by Bengala et al (2005), who performed a phase I study of gemcitabine infusion at a fixed dose rate in patients with pancreatic cancer, and also investigated the relationship between CDA mRNA expression in peripheral blood mononuclear cells and clinical outcome.